

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
<b>CONVEYING PARTY DATA</b>											
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Philipp KRASTEL</td> <td>08/05/2008</td> </tr> <tr> <td>Brigitta-Maria LIECHTY</td> <td>08/15/2008</td> </tr> <tr> <td>Esther SCHMITT</td> <td>08/05/2008</td> </tr> <tr> <td>Erwin Paul SCHREINER</td> <td>08/01/2008</td> </tr> </tbody> </table>		Name	Execution Date	Philipp KRASTEL	08/05/2008	Brigitta-Maria LIECHTY	08/15/2008	Esther SCHMITT	08/05/2008	Erwin Paul SCHREINER	08/01/2008
Name	Execution Date										
Philipp KRASTEL	08/05/2008										
Brigitta-Maria LIECHTY	08/15/2008										
Esther SCHMITT	08/05/2008										
Erwin Paul SCHREINER	08/01/2008										
<b>RECEIVING PARTY DATA</b>											
Name:	Novartis AG										
Street Address:	Lichtstrasse 35										
City:	Basel										
State/Country:	SWITZERLAND										
Postal Code:	4056										
<b>PROPERTY NUMBERS Total: 1</b>											
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>12673785</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	12673785						
Property Type	Number										
Application Number:	12673785										
<b>CORRESPONDENCE DATA</b>											
Fax Number:	(617)871-3392										
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>											
Email:	nibr.maildata@novartis.com										
Correspondent Name:	Katherine Kantorski										
Address Line 1:	Novartis Institutes for BioMedical Resea										
Address Line 2:	220 Massachusetts Avenue										
Address Line 4:	Cambridge, MASSACHUSETTS 02139										
ATTORNEY DOCKET NUMBER:	PAT052209-US-PCT										
NAME OF SUBMITTER:	Katherine Kantorski										

CH \$40.00 12673785

Total Attachments: 7  
 source=Assignment\_52209#page1.tif

**501588643**

**PATENT**  
**REEL: 026560 FRAME: 0579**

source=Assignment\_52209#page2.tif  
source=Assignment\_52209#page3.tif  
source=Assignment\_52209#page4.tif  
source=Assignment\_52209#page5.tif  
source=Assignment\_52209#page6.tif  
source=Assignment\_52209#page7.tif

**ASSIGNMENT**

For good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, we

Philipp KRASTEL	citizen of Germany	Hauptstrasse 13 79639 Grenzach-Wyhlen Germany
Brigitta-Maria LIECHTY	citizen of Switzerland	Kleinhueningerstrasse 140 4057 Basel
Esther SCHMITT	citizen of Germany	Mauerstr. 6 79539 Lörrach DE
Erwin Paul SCHREINER	citizen of Austria	Novartis Institutes for BioMedical Research GmbH & Co KG Brunner Strasse 59 1235 Wien AT

do hereby sell, assign and transfer to **Novartis AG**, a company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland, and its successors, assigns and legal representatives, all our right, title and interest for all countries of the world (Novartis AG hereinafter referred to as the "**ASSIGNEE**") in and to (1) all of our inventions and discoveries described in the patent application(s) entitled

**USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7**

filed\* in the RO/ on 14 August, 2008, and accorded International Patent Application Number PCT/EPO8/060693, (2) said patent application(s), (3) all national stages of said international patent application, (4) all other patent applications in all countries and regions claiming the priority of the European Procedure, patent application filed on August 17, 2007 and accorded Application Number 07114505.6 (5) all continuations and divisions of all of said patent applications (including further continuations and divisions such as, but not limited to, continuations of continuations and continuations of divisions), ((2)-(5) hereinafter referred to collectively as "patent applications"), (6) all patents that are granted on any of said patent applications, (7) all registrations and confirmations of, and importation certificates based on, one or more of said patents and (8) all reissues, renewals and extensions of said patents, reexamination certificates issued for said patents and supplementary protection certificates based on said patents (including the right to file patent applications on said inventions and discoveries in the names of **ASSIGNEE**, their designees or in any or all of our names, at their election and in accordance with applicable law in all countries and regions and all rights of priority in all countries and regions for all of said patent applications under the International Convention for the Protection of Industrial Property, and all other applicable similar international agreements), the same to be held and enjoyed by said **ASSIGNEE**, their successors, assigns and legal representatives, to the full ends of the terms for which all patents therefor may

be granted, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made.

\*We hereby authorize **ASSIGNEE** and their representatives to insert in this instrument the Application Number and the filing date of said patent application when notified thereof.

And we hereby covenant and agree that we will, at any time, upon the request and at the expense of **ASSIGNEE**, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, patent applications, patents, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates and supplementary protection certificates in **ASSIGNEE**, their successors, assigns or other legal representatives, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, that we will, at any time, upon the request and at the expense of **ASSIGNEE**, execute all additional patent applications, applications for registration and/or confirmation of one or more of said patents, applications for certificates of importation based on one or more of said patents, applications for reissues, renewals and extensions of one or more of said patents and supplemental protection certificates based upon one or more of said patents, and that we will make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of **ASSIGNEE**, the successors, assigns or other legal representatives.

X Executed this 05 day of AUGUST, 2008.

X Philipp Krastel L.S.  
Name: Philipp Krastel

X Executed this 15 day of August, 2008.

X Brigitta-Maria Liechty L.S.  
Name: Brigitta-Maria Liechty

X Executed this 05 day of August, 2008.

X Esther Schmitt L.S.  
Name: Esther Schmitt

Executed this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_\_.

\_\_\_\_\_  
Name: Erwin Paul Schreiner

**ACCEPTANCE OF ASSIGNMENT**

With reference to the Assignment to **NOVARTIS AG** of an invention entitled "**USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7**" signed by Philipp Krastel, Brigitta-Maria Liechty, Esther Schmitt, and Erwin Paul Schreiner; this will certify that **NOVARTIS AG** accepts such Assignment.

**NOVARTIS AG**

By :

  
\_\_\_\_\_

  
\_\_\_\_\_

Name :

Ella Rutschmann  
\_\_\_\_\_

Reto Halbeisen  
\_\_\_\_\_

Function :

IP Administrative Expert  
\_\_\_\_\_

IP Administrative Expert  
\_\_\_\_\_

Date:

15 August 2008  
\_\_\_\_\_

**ASSIGNMENT**

For good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, we

Philipp KRASTEL	citizen of Germany	Hauptstrasse 13 79639 Grenzach-Wyhlen Germany
Brigitta-Maria LIECHTY	citizen of Switzerland	Kleinhueningerstrasse 140 4057 Basel
Esther SCHMITT	citizen of Germany	Mauerstr. 6 79539 Lörrach DE
Erwin Paul SCHREINER	citizen of Austria	Novartis Institutes for BioMedical Research GmbH & Co KG Brunner Strasse 59 1235 Wien AT

do hereby sell, assign and transfer to **Novartis AG**, a company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland, and its successors, assigns and legal representatives, all our right, title and interest for all countries of the world (Novartis AG hereinafter referred to as the "**ASSIGNEE**") in and to (1) all of our inventions and discoveries described in the patent application(s) entitled

**USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7**

filed\* in the RO/ on 14 August, 2008, and accorded International Patent Application Number PCT/EP 08/060693, (2) said patent application(s), (3) all national stages of said international patent application, (4) all other patent applications in all countries and regions claiming the priority of the European Procedure, patent application filed on August 17, 2007 and accorded Application Number 07114505.6 (5) all continuations and divisions of all of said patent applications (including further continuations and divisions such as, but not limited to, continuations of continuations and continuations of divisions), ((2)-(5) hereinafter referred to collectively as "patent applications"), (6) all patents that are granted on any of said patent applications, (7) all registrations and confirmations of, and importation certificates based on, one or more of said patents and (8) all reissues, renewals and extensions of said patents, reexamination certificates issued for said patents and supplementary protection certificates based on said patents (including the right to file patent applications on said inventions and discoveries in the names of **ASSIGNEE**, their designees or in any or all of our names, at their election and in accordance with applicable law in all countries and regions and all rights of priority in all countries and regions for all of said patent applications under the International Convention for the Protection of Industrial Property, and all other applicable similar international agreements), the same to be held and enjoyed by said **ASSIGNEE**, their successors, assigns and legal representatives, to the full ends of the terms for which all patents therefor may

be granted, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made.

\*We hereby authorize **ASSIGNEE** and their representatives to insert in this instrument the Application Number and the filing date of said patent application when notified thereof.

And we hereby covenant and agree that we will, at any time, upon the request and at the expense of **ASSIGNEE**, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, patent applications, patents, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates and supplementary protection certificates in **ASSIGNEE**, their successors, assigns or other legal representatives, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, that we will, at any time, upon the request and at the expense of **ASSIGNEE**, execute all additional patent applications, applications for registration and/or confirmation of one or more of said patents, applications for certificates of importation based on one or more of said patents, applications for reissues, renewals and extensions of one or more of said patents and supplemental protection certificates based upon one or more of said patents, and that we will make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of **ASSIGNEE**, the successors, assigns or other legal representatives.

Executed this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_\_.

\_\_\_\_\_  
Name: Philipp Krastel L.S.

Executed this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_\_.

\_\_\_\_\_  
Name: Brigitta-Maria Liechty L.S.

Executed this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_\_.

\_\_\_\_\_  
Name: Esther Schmitt L.S.

Executed this 1st day of August, 2008.

  
Name: Erwin Paul Schreiner L.S.

**ACCEPTANCE OF ASSIGNMENT**

With reference to the Assignment to **NOVARTIS AG** of an invention entitled "**USE OF CYCLIC DEPSIPEPTIDES TO INHIBIT KALLIKREIN 7**" signed by Philipp Krastel, Brigitta-Maria Liechty, Esther Schmitt, and Erwin Paul Schreiner; this will certify that **NOVARTIS AG** accepts such Assignment.

**NOVARTIS AG**

By :

E. Rutschmann

R. Halbeisen

Name :

Ella Rutschmann

Reto Halbeisen

Function :

IP Administrative Expert

IP Administrative Expert

Date:

15 August 2008




### Attestation

I, the undersigned notary public in Basel, Switzerland, Dr. Andreas C. Albrecht, certify herewith that the above signatures are the genuine signatures of **Mr. Philipp Krastel**, German citizen, residing in Grenzach-Wyhlen, Germany; of **Ms. Brigitta-Maria Liechty**, citizen of Riehen/BS, Switzerland, residing in Basel, Switzerland; of **Ms. Esther Schmitt**, German citizen, residing in Lörrach, Germany; and of **Dr. Erwin Paul Schreiner**, Austrian citizen, residing in Vienna, Austria.

Further I certify that the above signatures are the genuine signatures of **Mrs. Ella Rutschmann**, citizen of Lotzwil, Switzerland, residing in Basel, Switzerland, and **Mr. Reto Halbeisen**, citizen of Wahlen/BL, Switzerland, residing in Laufen, Switzerland both acting for **Novartis AG**, in Basel, Switzerland, both as proxy holders, both with joint signature.

The authenticity of the signatures was established by comparison.

BASEL, Switzerland, this 2<sup>nd</sup> (second) day of September 2008 (twothousandandeight)



A. Albrecht,  
Notar

Dr. A.C. Albrecht  
Notar

Leg.Prot.Nr.: 496/2008